SonoScape Medical Corp (300633) Fair Value & Analysis
Healthcare · CN · Market cap 8.2B CNY
Fair value as of: Jul 9, 2026
From 15 valuation models · updated 32 days ago
Fair value updated Jul 9, 2026, revised from ¥9.55 to ¥17.19 (+80.0%) since Jun 24, 2026. Share price +9.1% over the past month.
A solid business, but screening 15% overvalued on our models.
What matters now
- Solid but not exceptional quality (55/100) and above fair value, neither a clear bargain nor a standout compounder.
- A fairly wide model range (¥12.04 to ¥21.83) leaves room in how you read the outcome.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 9, 2026.
How to read this chart
60‑month range ¥17.97 – ¥59.72 · fair‑value band ¥12.04 – ¥21.83 · the ¥20.33 price screens above the ¥17.19 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Jul 9, 2026.
Analysis
SonoScape Medical Corp (300633) currently trades at ¥20.33, while our model-based Fair Value estimate is ¥17.19, implying the stock looks roughly 15.5% overvalued today. The Quality Score stands at 55/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).
Over the trailing twelve months, SonoScape Medical Corp generated revenue of 2.4B CNY at a net margin of 7.5%. Revenue grew 11.8% year over year. It earns a return on equity of 5.6%. The balance sheet holds a net cash position of 1.2B CNY. Fundamentals as of Jul 9, 2026
Our scenario range runs from ¥12.04 (bear case) to ¥21.83 (bull case); at ¥20.33, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 46% below its 52-week high and 9% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -22% fair-value upside, at -15%, 300633 screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 15 models by family
Widest divergence: DCF Models (¥11.84) versus Asset-Based (¥5.15). Highest evidence: Residual Income (76).
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 9, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 55 · Market factors (momentum, volatility) 27
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
SonoScape Medical Corp., together with its subsidiaries, engages in the research, development, production, and sale of medical diagnosis and treatment equipment in China and internationally.
Full company description
SonoScape Medical Corp., together with its subsidiaries, engages in the research, development, production, and sale of medical diagnosis and treatment equipment in China and internationally. It offers ultrasound medical imaging products comprising trolley and portable color dopplers, B/W ultrasounds, and transducers; endoscopic diagnosis and treatment products consisting of image processors, light sources, gastroenterology and pulmonology products, endoscopic ultrasound, duodenoscopes, and peripheral equipment; minimally invasive surgery solutions, such as camera systems and flexible endoscopes; veterinary ultrasound and endoscopy solutions; and intravascular intervention products. The company also provides face-to-face and online training for ultrasound and endoscopy systems; technical and spare parts support; preventive maintenance, calibration, breakdown repair, and other field services; and upgrade services. In addition, it is involved in the software industry. SonoScape Medical Corp. was incorporated in 2002 and is headquartered in Shenzhen, China.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
SonoScape Medical Corp reported revenue of ¥2.3B in FY2025 versus ¥1.4B in FY2021, a compound +12.4%/yr. Reported net income was ¥197M in FY2025, compounding −5.5%/yr from FY2021.
300633 screens 15% overvalued. Compare with Abbott Laboratories, →
Peer Group
Medical Devices · 351 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Medical Devices median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Medical Devices stocks, each showing price versus our Fair Value estimate (as of Jul 9, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Abbott Laboratories, ABT | $100.68 | $74.79 | -26% |
| Stryker Corporation SYK | $316.44 | $186.28 | -41% |
| Medtronic plc MDT | $83.56 | $65.57 | -22% |
| Boston Scientific Corporation BSX | $43.04 | $38.44 | -11% |
| Edwards Lifesciences Corporation EW | $85.73 | $41.02 | -52% |
| Siemens Healthineers AG SHL | €34.59 | €33.87 | -2% |
| Shenzhen Mindray Bio-Medical Electronics Co 300760 | ¥149.43 | ¥147.63 | -1% |
| Shanghai United Imaging Healthcare Co 688271 | ¥109.00 | ¥43.60 | -60% |
| Demant A/S DEMANT | kr 276.60 | kr 161.17 | -42% |
| Getinge AB GETIB | kr 206.80 | kr 192.14 | -7% |
Compare SonoScape Medical Corp with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is SonoScape Medical Corp (300633) overvalued or undervalued?
What is the fair value of 300633?
What is the quality score of 300633?
What is the revenue of SonoScape Medical Corp (300633)?
What is the net profit margin of 300633?
Does SonoScape Medical Corp pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track SonoScape Medical Corp and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.